Core Viewpoint - The recent surge in the stock prices of CanSino Biologics (6185.HK) is attributed to a warning from the World Health Organization regarding mosquito-borne diseases, particularly Chikungunya fever, which has heightened market sentiment towards the vaccine sector [1]. Group 1: Stock Performance - CanSino Biologics experienced a significant stock increase, rising over 16.8% to a peak of 55.7 HKD, marking a new high since March 2023 [1]. - The A-share market also saw a rise of over 11%, reaching a maximum of 92.7 CNY, the highest since August 2023 [1]. Group 2: Disease Outbreak - The Guangdong Provincial Center for Disease Control reported 2,892 new local cases of Chikungunya fever from July 27 to August 2 [1]. Group 3: Product Development - CanSino has made important advancements in the research and commercialization of multiple products in the second half of this year [1]. - The company announced that its trivalent inactivated poliovirus vaccine (Sf-RVN cells) has received approval from the National Medical Products Administration of China to commence clinical trials [1]. - On June 20, CanSino disclosed that its 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxin) has been approved for new drug listing by the National Medical Products Administration [1].